Table 3.

Associations between hyperoncotic albumin exposure and outcomes among the propensity score matched patients

Primary outcome	Albumin N = 3600	Control N = 3600	Odds ratio (95% CI) (albumin/control)	P value
Acute kidney injury			1.10 (1.04, 1.17)	0.002
No injury	2610 (72.5)	2699 (75.0)
Stage 1 injury	729 (20.3)	704 (19.6)
Stage 2 injury	104 (2.9)	90 (2.5)
Stage 3 injury	157 (4.4)	107 (3.0)
Secondary outcomes			Odds ratio (98.3% CI)†
Liver injury	137 (3.8)	118 (3.3)	1.16 (0.85, 1.58)	0.25
In-hospital mortality	114 (3.2)	127 (3.5)	0.88 (0.64, 1.20)	0.32
			Hazard ratio (98.3% CI) †
Length of ICU stay‡ (h)	64 [41, 119]	50 [29, 115]	0.95 (0.90, 1.00)	0.03

^†P value < 0.017 was considered significant (i.e., 0.05/3 = 0.017, Bonferroni correction)

^‡Discharges for those patients who died in hospital were considered as non-events and censored at the longest observed length of stay